Blinding in pharmacological trials: the devil is in the details.
作者信息
Wan Mandy, Orlu-Gul Mine, Legay Helene, Tuleu Catherine
机构信息
National Institute for Health Research-Medicines for Children Research Network-London & South East, Evelina London Children's Hospital, Guy's and St Thomas NHS Foundation Trust, King's Health Partners, London, UK.
出版信息
Arch Dis Child. 2013 Sep;98(9):656-9. doi: 10.1136/archdischild-2013-304037. Epub 2013 Jul 29.
Abstract
摘要
相似文献
1
Blinding in pharmacological trials: the devil is in the details.
Arch Dis Child. 2013 Sep;98(9):656-9. doi: 10.1136/archdischild-2013-304037. Epub 2013 Jul 29.
2
Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
J Clin Epidemiol. 2021 Jul;135:176-181. doi: 10.1016/j.jclinepi.2021.02.022. Epub 2021 Mar 1.
3
Double-blinding in clinical trials.
CMAJ. 1989 Jan 1;140(1):15.
4
The landscape and lexicon of blinding in randomized trials.
Ann Intern Med. 2002 Feb 5;136(3):254-9. doi: 10.7326/0003-4819-136-3-200202050-00022.
5
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
Circulation. 2004 Jun 1;109(21):e302-4. doi: 10.1161/01.CIR.0000128807.57602.61.
6
Verapamil in mania.
Am J Psychiatry. 1993 Mar;150(3):529-30. doi: 10.1176/ajp.150.3.529.
7
Ten Practical Recommendations for Improving Blinding Integrity and Reporting in Psychotherapy Trials.
JAMA Psychiatry. 2021 Sep 1;78(9):943-944. doi: 10.1001/jamapsychiatry.2021.1419.
8
Inert placebo versus active medication. Patient blindability in clinical pharmacological trials.
J Nerv Ment Dis. 1994 Sep;182(9):485-7. doi: 10.1097/00005053-199409000-00001.
9
The design of controlled experiments in the evaluation of non-therapeutic interventions.
J Chronic Dis. 1982;35(7):531-8. doi: 10.1016/0021-9681(82)90072-8.
10
Clinical trials of acupuncture: consensus recommendations for optimal treatment, sham controls and blinding.
Complement Ther Med. 2001 Dec;9(4):237-45. doi: 10.1054/ctim.2001.0489.
引用本文的文献
1
Co-created in vivo pharmacology practical classes using the novel organism Lumbriculus variegatus.
Pharmacol Res Perspect. 2023 Dec;11(6):e01158. doi: 10.1002/prp2.1158.
2
Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials.
Cureus. 2023 Aug 28;15(8):e44244. doi: 10.7759/cureus.44244. eCollection 2023 Aug.
3
Research trends in the field of the gut-brain interaction: Functional dyspepsia in the spotlight - An integrated bibliometric and science mapping approach.
Front Neurosci. 2023 Mar 8;17:1109510. doi: 10.3389/fnins.2023.1109510. eCollection 2023.
4
Manual Therapy Effect in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
Int J Environ Res Public Health. 2022 Oct 28;19(21):14021. doi: 10.3390/ijerph192114021.
5
Complementary and alternative medicine for functional dyspepsia: An Asian perspective.
Medicine (Baltimore). 2022 Sep 2;101(35):e30077. doi: 10.1097/MD.0000000000030077.
6
Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials units.
Trials. 2022 Jun 27;23(1):535. doi: 10.1186/s13063-022-06481-9.
7
Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial): A Randomized Controlled Trial: Background, Aims and Study Protocol.
Front Pain Res (Lausanne). 2021 Dec 7;2:770511. doi: 10.3389/fpain.2021.770511. eCollection 2021.
8
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD013167. doi: 10.1002/14651858.CD013167.pub2.
9
Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models.
Vaccines (Basel). 2021 Aug 11;9(8):890. doi: 10.3390/vaccines9080890.
10
Blinding in Clinical Trials: Seeing the Big Picture.
Medicina (Kaunas). 2021 Jun 24;57(7):647. doi: 10.3390/medicina57070647.
本文引用的文献
1
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3.
2
The unobtainable placebo: control of independent clinical research by industry?
Lancet. 2012 Jan 7;379(9810):30. doi: 10.1016/S0140-6736(12)60024-5.
3
Blinding in randomized clinical trials: imposed impartiality.
Clin Pharmacol Ther. 2011 Nov;90(5):732-6. doi: 10.1038/clpt.2011.207. Epub 2011 Oct 12.
4
Explanatory and pragmatic clinical trials: a primer and application to a recent asthma trial.
Pol Arch Med Wewn. 2011 Jul-Aug;121(7-8):259-63.
5
Clinical trials and tribulations: the MASCOT study.
Thorax. 2011 Jun;66(6):457-8. doi: 10.1136/thx.2010.156885. Epub 2011 Mar 11.
6
Products at risk.
N Engl J Med. 2010 Oct 28;363(18):1763. doi: 10.1056/NEJMe1010348. Epub 2010 Sep 19.
7
Inappropriate oral formulations and information in paediatric trials.
Arch Dis Child. 2010 Sep;95(9):754-6. doi: 10.1136/adc.2009.175661. Epub 2010 Jul 6.
8
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.
Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24.
9
What are excipients doing in medicinal products?
Drug Ther Bull. 2009 Jul;47(7):81-4. doi: 10.1136/dtb.2009.06.0026.
10
Improving the reporting of pragmatic trials: an extension of the CONSORT statement.
BMJ. 2008 Nov 11;337:a2390. doi: 10.1136/bmj.a2390.
Zotero 插件